12:00 AM
 | 
Aug 24, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Hiberix regulatory update

FDA granted accelerated approval to a BLA from GlaxoSmithKline for Hiberix Haemophilus influenzae type B (Hib) vaccine as a booster dose for children ages 15 months to 4 years. The accelerated approval came in...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >